SUVENPHAR2024-01-012024-03-31 SUVENPHAR2024-01-012024-03-31 SUVENPHAR2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2024-03-31 SUVENPHAR2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUVENPHAR2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUVENPHAR2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SUVENPHAR2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2023-04-01 2024-03-31 2024-05-30 2024-05-21 INR Lakhs Yearly 16:00:00 17:25:00 2024-05-30 2024-05-30 true Cash Flow Indirect Declaration of unmodified opinion Single segment Contract Development and Manufacturing 2024-01-01 2024-03-31 Unaudited Consolidated 2529304000.00 170537000.00 2699841000.00 714253000.00 0.00 122950000.00 393889000.00 22995000.00 172461000.00 564773000.00 1991321000.00 708519000.00 0.00 708519000.00 185452000.00 -10665000.00 174788000.00 0.00 533732000.00 0.00 0.00 0.00 0.00 533732000.00 140400000.00 674132000.00 0.00 0.00 0.00 0.00 254565000.00 1 2.10 2.10 0.00 0.00 2.10 2.10 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the BOD at their respective meetings held on 30.05.2024. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended 31.03.2024 and have issued an unmodified conclusion in respect of the limited review for the qtr ended 31.03.2024. 2) The above financial results have been prepared in accordance with the Companies (IndAS) Rules, 2015 (Ind AS) as amended, prescribed under Sec 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the WOSs Suven Pharma, Inc.,USA & Casper Pharma Pvt Ltd.4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.5) As per share purchase agreement dated 26.12.2022 entered into by and between Berhyanda Ltd (Buyer), Jasti Property and Equity Holdings Pvt Ltd (in their capacity as sole trustee of Jasti Family Trust) (Seller) and Mr.Venkatesearlu Jasti (Seller representative) pursuant to SEBI SAST Regulations, 2011 as amended, M/s Berhyanda Ltd, a Cyprus based company and an investment arm of Adven International Corporation , USA has acquired controlling stake to the tune of 12,75,37,043 eq shares aggregating to 50.10% in the company on 29.09.2023 from the seller. In addition to above, Berhyanda Ltd acquired 2,549 equity shares from public in open offer.6)The Company instituted an Employee stock option scheme 2023( ESOP ) to eligible employees which provides for a grant of 1,25,00,000 options (each option convertible into 1 equity share based on Multiple of Money (MOM) matrix) to employees. From the above pool, 65,94,308 options are granted by (NRC) on the Grant date of option being 24.02.2024. Accordingly, the employee benefit expense for the quarter ended 31 March, 2024 includes charge of Rs. 199.5 Lakhs towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.7)The Board of Directors of Suven Pharmaceuticals Limited (Company) at their meeting held on 29th February 2024), had considered and approved a scheme of amalgamation of Cohance Lifesciences Limited (“Transferor Company”) into and with the Company and their respective shareholders and creditors under the applicable provisions of law. The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon’ble National Company Law Tribunal, SEBI, Department of Pharmaceuticals (if such approval is required pursuant to applicable laws), Stock Exchanges and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.8)The Board of Directors of Suven Pharmaceuticals Limited (Company) at their meeting held on 29th February, 2024), had considered and approved a scheme of amalgamation of Casper Pharma Private Limited (“Transferor Company”) (a wholly owned subsidiary of the Company) into and with the Company and their respective shareholders and creditors under the applicable provisions of law. The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon’ble National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.9) The figures for the current quarter ended 31st March, 2024 and quarter ended 31st March, 2023 are the balancing figures between the audited figures in respect of the full financial year ended 31st March, 2024 and 31st March, 2023 respectively and published year to date figures up to third quarter ended 31st December, 2023 and 31st December , 2022 respectively, which are subject to limited review by the statutory auditors.10) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2023-04-01 2024-03-31 Audited Consolidated 10513537000.00 619051000.00 11132589000.00 2658790000.00 0.00 491555000.00 1359202000.00 74511000.00 545956000.00 1945857000.00 7075872000.00 4056716000.00 0.00 4056716000.00 987989000.00 65921000.00 1053910000.00 0.00 3002806000.00 0.00 0.00 0.00 0.00 3002806000.00 132041000.00 3134847000.00 0.00 0.00 0.00 0.00 254565000.00 1 20252070000.00 11.80 11.80 0.00 0.00 11.80 11.80 Manufacturing Expenses 365389000.00 Other Expenses 199384000.00 Manufacturing Expenses 1334760000.00 Other Expenses 611097000.00 5672192000.00 1789716000.00 0.00 0.00 1024006000.00 1103000.00 0.00 0.00 1305819000.00 75000.00 93720000.00 1399613000.00 22371000.00 9909002000.00 2311957000.00 7738956000.00 1336592000.00 472312000.00 32677000.00 8308000.00 4288000.00 9593132000.00 99844000.00 626931000.00 12631864000.00 0.00 0.00 22540865000.00 254565000.00 20252070000.00 20506635000.00 20506635000.00 0.00 0.00 212356000.00 212356000.00 105004000.00 647912000.00 0.00 0.00 965273000.00 385753000.00 423574000.00 140220000.00 949546000.00 71974000.00 47437000.00 0.00 0.00 1068957000.00 0.00 0.00 2034230000.00 22540865000.00 74511000.00 816149000.00 -228023000.00 0.00 354504000.00 -238239000.00 0.00 0.00 0.00 -281738000.00 0.00 42722000.00 0.00 518059000.00 0.00 3927000.00 22054000.00 -17238000.00 0.00 6641000.00 0.00 19348000.00 0.00 0.00 0.00 -448430000.00 0.00 22071000.00 0.00 627621000.00 4684338000.00 0.00 0.00 0.00 1099507000.00 0.00 3584831000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 517869000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11100000.00 3111601000.00 0.00 0.00 0.00 0.00 0.00 19348000.00 0.00 -23510000.00 0.00 -3622532000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 315935000.00 0.00 -252423000.00 0.00 74511000.00 0.00 0.00 -138023000.00 -175724000.00 9000.00 -175716000.00 648028000.00 472312000.00 Items that will not be reclassified to profit or loss 12208000.00 Items that will not be reclassified to profit or loss 1037000.00 12208000.00 1037000.00 1820000.00 -992000.00 Items that will be reclassified to profit or loss 130012000.00 Items that will be reclassified to profit or loss 130012000.00 130012000.00 130012000.00 0.00 0.00